Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver Resection

Effect of Continuity of Care on Emergency Department Visits in Elderly Patients with Asthma in Taiwan

“…The accuracy of the data and diagnoses retrieved from the database has been validated. 28 This study protocol was reviewed and approved by the Institutional Review Board of National Yang-Ming University, Taiwan (approval no. YM103047E).…”

Current management of hepatocellular carcinoma: An Eastern perspective

“…Interferon has been suggested as an adjuvant therapy after resection [130] . According to a large current database in Taiwan, antiviral therapies reduce the recurrence of HCC after surgery in patients with chronic hepatitis B or C [131,132] . In agreement, a randomized controlled trial conducted in China showed better recurrence-free survival (RR = 0.651, 95%CI: 0.451-0.938) and overall survival (RR = 0.420, 95%CI: 0.271-0.651) in patients receiving antiviral therapy, especially in terms of prevention of late recurrence [133] .…”

“…In agreement, a randomized controlled trial conducted in China showed better recurrence-free survival (RR = 0.651, 95%CI: 0.451-0.938) and overall survival (RR = 0.420, 95%CI: 0.271-0.651) in patients receiving antiviral therapy, especially in terms of prevention of late recurrence [133] . It would be reasonable to recommend nucleoside or nucleotide analogues or interferon therapy to patients with hepatitis B and pegylated interferonbased therapy to patients with hepatitis C after curative hepatic resection [130][131][132][133] .…”

Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy

“…The only two randomized trials (19,20) that we identified in literature searches, as well as large cohort studies (18,19,21) examining NA therapy, found that it significantly reduced late HCC recurrence and improved long-term overall survival in patients with HBV-associated HCC following curative hepatectomy. However, the therapy fails to provide obvious clinical benefits for reducing early tumor recurrence or improving short-term overall survival (18)(19)(20)(21). This may reflect the fact that the majority of patients in these trials (19,20) were in the early stages of HCC.…”

“…Postoperative antiviral therapy with NAs is another therapy commonly used following hepatectomy in patients with HBV-associated HCC (17,18). The goal of postoperative antiviral therapy in HBV-associated HCC is to reduce the viral load of HBV, protect liver function, decrease tumor recurrence, increase overall survival and improve quality of life.…”